Private investment vehicle funded by entrepreneurial families.
a successful life sciences investor with a 20 year track record.
Active investors. Strongly involved in mentoring the management.
A worldwide network in the life sciences and family office spaces.
Great ideas/entrepreneurs need more than capital, they need guidance from experienced business people.
Source and finance innovative medical technologies that with our enthusiastic assistance can be developed into leading businesses.
Companies that need a strategic investor in order to overcome milestones/challenges.
Later stage ventures that have undergone significant due diligence and contain strong market experience yielding a lower intrinsic risk..
Iproteos is an award-winning biotechnology company, spun out of the Institute for research in Biomedicine/University of Barcelona. It specializes in the development of third-generation peptidomimetics. Their drug discovery platform IPROTech profits from a vast proprietary database of molecules able to modulate the activity of currently undruggable targets, such as Protein-Protein Interactions(PPIs).
Iproteos has a strong drug pipeline with two main pre-clinical projects; Cognitive impairment associated with schizophrenia(CIAS) and Epileptogenesis.
Spiral therapeutics is an American/Spanish biotechnology company focused in tackling Inner Ear Disorders. They are currently developing two compounds that will be able to prevent hearing loss in patients suffering from several indications. SpiralTX is successfully building a bridge between the Silicon Valley and Catalonia, being able to profit the best from both worlds.
OMICTools is the biggest community search platform that provides life sciences researchers an easy and effective way of searching and comparing computational biology tools and related databases that can aid on their research projects. OMICTools is currently used by most of the world’s biggest pharmaceutical companies and renowned biomedicine research institutions and universities.
EVELIQURE BIOTECHNOLOGIES is an Austrian biotechnology company focused on providing efficacious vaccines to reduce the high burden of diarrheal diseases among travellers and young children living in developing countries. They are currently developing the first combination Shigella-ETEC vaccine using their novel vaccine technology platform, to prevent 500 thousand child deaths caused each year. According to the Bill & Melinda Gates Foundation PATH study, global demand for a successful ETEC vaccine is estimated to reach 118 million doses per year.
Hence our approach is very unique as we:
We invite like minded entrepreneurs to join with us in specific projects.